A New Method for the Screening of Unidentified Complaints Syndrome in Pre-, Mid- and Post menopausal Women
|
|
- Opal Hopkins
- 5 years ago
- Views:
Transcription
1 Tohoku J. exp. Med., 1975, 116, A New Method for the Screening of Unidentified Complaints Syndrome in Pre-, Mid- and Post menopausal Women TETSURO ABE, NOBUAKI FURUHASHI, ICHIO OHASHI, MASAKUNI SUZUKI and TAKEJIRO MORITSUKA* Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai and Department of Obstetrics and Gynecology,* National Sendai Hospital, Sendai ABE, T., FURUHASHI, N., OHASHI, I., SUZUKI, M. and MORITSUKA, T. A New Method for the Screening of Unidentified Complaints Syndrome in Pre-, Midand Postmenopausal Women. Tohoku J. exp. Med., 1975, 116 (1), A new simple test for the screening of pre-, mid- and post-menopausal women with unidentified complaints overlaid by psychiatric disorders has been devised. This test is performed by intravenous injection of conjugated estrogen and by comparing Kupperman's menopausal indices before and after the injection. That is, the discriminant function between groups with and without psychiatric abnormalities was obtained from Kupperman's menopausal indices before and after intravenous injection of conjugated estrogen, and from this function was made a calculative differential diagnosis between the two groups. The calculative diagnosis agreed fairly well with the clinical diagnosis by the psychiatrist. climacteric symptoms; menopausal symptoms; discriminant function; conjugated estrogen; Kupperman's menopausal index It has been generally accepted that the basic treatment for the menopausal symptoms should include hormonal therapy designed to correct estrogen insuffi ciency and psychotherapy (Dilts et al. 1971; Kistner 1972). However, symptom atological and therapeutical analyses of the menopausal symptoms are not yet complete and need more precise and objective studies. Unidentified complaints syndrome has been defined as a group of symptoms composed of vague somatic complaints, such as hot flushes, sweats, chilly sensation, numbness, general malaise, dull headache, etc., without any identifiable objective signs accountable for the complaints. The authors administered conjugated estrogen to pre-, mid- and post-meno pausal women with the unidentified complaints syndrome in an attempts to differentiate the psychiatrically disordered cases among them according to the effect of conjugated estrogen on their symptoms. Receivad for publication. February 3, Reprint requests: Dr. Tetsuro Abe, Dept. of Ob/Gyn., Tohoku University School of Medicine, 1-1 Seiryo-machi, Sendai 980, Japan. 81
2 82 T. Abe et al. SUBJECTS AND METHODS Eighty six women with the unidentified complaints who showed no sign of either gynecological or any other somatic diseases were subjected to this study. First, they were requested to fill a questionnaire (Table 1) containing 11 items concern ing various kinds of symptoms, and on the basis of which Kupperman's menopausal index (Kupperman et al. 1959) was calculated. Then, the patients were given an intravenous injection of 20 mg of conjugated estrogen (Premarin) and the menopausal index was calculated again at 3 or 4 days after injection. Subsequently, they were entrusted to psychiatrists to determine the presence or absence of psychiatric abnormalities. They were divided into two groups, one with and the other without psychiatric abnormalities, accord ing to the diagnosis by the psychiatrists. A comparison was made between the two groups with respect to the effect of conjugated estrogen on the menopausal index. Secondly, the conjugated estrogen or placebo was injected intravenously into the women without psychiatric abnormalities in order to evaluate the effect of conjugated estrogen on the unidentified complaints by the double blind test, comparing menopausal indices before and after injection. TABLE 1. Questionnaire for the calculation of Kupperman's menopausal index Items representing symptoms are the same as in Kupperman's method (Kupperman 1959). EXPERIMENTAL RESULTS Of 86 women 17 were with psychiatric abnormalities and 69 without them. There was no significant difference in age between the two groups of the patients, as shown in Table 2. Psychiatric abnormalities included neurosis in 16 cases (94 %) and schizophrenia in 1 case (6%). Fig. 1 shows the menopausal indices calculated before and after administration of conjugated estrogen. The indices before administration are represented on the abscissa and those after administration on the ordinate. The psychiatrically abnormal group is indicated by the closed circles and the psychiatrically normal group by the open circles. The majority of the patients in the normal group
3 Screening of Unidentified Complaints in Menopausal Women 83 TABLE 2. Composition of the groups with and without psychiatric abnormalities of women complaining of the unidentified complaints as for the age Fig. 1. Effect of intravenous injection of conjugated estrogen on Kupperman's menopausal indices of women with the unidentified complaints. œ, psychiatrically abnormal group; ü, psychiatrically normal group. showed a decrease of the menopausal index after intravenous injection of conjugat ed estrogen, while most of the abnormal group showed little change. This difference in the reaction to the conjugated estrogen between the two groups was proved to be significant by the t-test (p<0.01) (Table 3). With Kupperman's menopausal indices determined before and after admin istration of conjugated estrogen, expressed as variables X0 and X1, respectively, a discriminant function between the two groups was calculated by the following formula: The values of X0 and Xl of each woman were applied to this formula. When Y was positive, she was classified into the normal group ; when negative, she was classified into the abnormal group. This calculative diagnosis was consistent with the clinical one in about 88.2% of the cases of the abnormal group and about 75.4% of the cases of the normal group.
4 84 T. Abe et al. TABLE 3. Factor analysis, with F-ratio, of the difference in Kupperman's menopausal indices between before and after administration of the psychiatrically abnormal and normal groups P, factor of group difference between the psychiatrically abnormal (Pl) and normal (P2) group; B (P), individual difference in Pl and P2; W, factor of time difference between before (W1) and after (W2) admin istration of conjugated estrogen; E, residue. * Significant difference at 1% level. In the next experiment, the patients without psychiatric abnormalities were given an intravenous injection of conjugated estrogen or placebo by the double blind method, in order to confirm the effect on the menopausal index. Fig. 2 shows the menopausal indices before and after intravenous injection: those before injection on the abscissa and those after injection on the ordinate. The closed circles indicate the conjugated estrogen group, and the open circles the placebo group. The results were analyzed by dividing the cases into two groups; one showed Fig. 2. Effect of intravenous injection of conjugated estrogen on Kupperman's menopausal indices of the psychiatrically normal group of women with the unidentified complaints. œ, conjugated estrogen-administered group; ü, placebo-administered group.
5 Screening of Unidentified Complaints in Menopausal Women 85 the menopausal index before intravenous injection less than 20, and the other showed the index of 20 or more. In the latter group, significant decreases of the index were observed after administration of conjugated estrogen (p<0.05 by t-test); while, in the former group, the conjugated estrogen did not exert any significant effect. DISCUSSION Although the basic treatment for the pre-, mid- and post-menopausal unidentified complaints has been thought to include hormonal therapy and psychotherapy (Dilts et al. 1971; Kistner 1972), indication of these therapies is not always clear at the moment. Only some, not all, of women complaining of the unidentified complaints seem to need psychotherapy. The presence or absence of psychiatric disorders is important for the choice of treatments because psychiatric treatments such as psychotherapy, rather than hormonal therapy, have to be primarily applied to the cases of women with psychiatric disorders. However, it is not easy for many busy physicians in gynecology to perform psychiatric examinations such as psychoanalysis, and a simple screening test for detection of psychiatric disorders is obviously useful for them. This is a reason why the author tried to devise a new method for screening psychiatrically disordered cases among women with unidentified complaints. On etiology of the menopausal symptoms, it has been said (titian 1972; Aitken et al. 1974) that the only symptom directly associated with the menopause is hot flushes and that other symptoms, such as depression, irritability, angina pectoris, insomnia and palpitation, are most likely of psychological origin. In the present study, the conjugated estrogen was proved, by the double blind test, to be strongly suggestive of exerting some specific effect for relief of the unidentified complaints of the pre-, mid- and post-menopausal women. However, since the physiological mechanism of the onset of menopausal symptom in relation to estrogen secretion has not yet been established at the moment, the significance of the decrease of Kupperman's menopausal index after intravenous injection of conjugated estrogen found in the cases of psychiatrically normal group should be studied in more detail in future. From the results of clinical evaluation of the author's new method for the screening of psychiatrically abnormal women (tentatively designated as 'Premarin test'), it was found that women diagnosed as having psychiatric disorders by the psychiatrist were screened by this method with about 88.2% accuracy. This suggests that the test is useful in actual clinical practice as a method for the screening of psychiatrically disordered cases among pre-, mid- and post menopausal women with unidentified complaints syndrome. References 1) Aitken, J.M., Davidson, A., England, P., Govan, A.D.T., Hart, D.M., Kelly, A., Rindsay, R. & Moffat, A. (1974) The relationship between menopausal vasomotor
6 86 T. Abe et al. symptoms and gonadotrophin excretion in urine after oophorectomy. J. Obstet. Gynec. Brit. Comm., 81, ) Dilts, P.V., Jr., Greene, J.W., Jr. & Roddick, J.W., Jr. (1971) Climacteric and menopause. In: Core Studies in Obstetrics and Gynecology, The Williams & Wilkins Co., Baltimore, p ) Kistner, R.W. (1972) The menopause. In: Gynecology, Principles and Practice. 2nd ed., edited by R.W. Kistner, Year Book Medical Publishers, Inc., Chicago, p ) Kupperman, H.S., Wetchler, B.B. & Blatt, M.H.G. (1959) Contemporary therapy of the menopausal syndrome. J. Amer. med. Ass., 171, ) Utian, W.H. (1972) The true clinical features of postmenopause and oophorectomy and their response to oestrogen therapy. S. Afr. med. J., 46,
Changes of Hypophysio-Ovarian Endocrinological Function by Aging in Women
Tohoku J. exp. Med., 1977, 121, 231-238 Changes of Hypophysio-Ovarian Endocrinological Function by Aging in Women NOBUAKI FURUHASHI, MASAKUNI SUZUKI, TETSURO ABE, YOSHIHIRO YAMAY A and KATSUYUKI TAKAHASHI
More information25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
More informationPsychiatric Symptomatology in Climacterium
Abstract Psychiatric Symptomatology in Climacterium Pages with reference to book, From 33 To 34 Muhammad Shafique ( Department of Psychiatry Khyber Medical College, Peshawar. ) A study of Psychiatric Symptomatology
More informationEvaluation Of The Efficacy And Tolerability Of Micronutrient Supplementation In Treatment Of Post Menopausal Symptoms
ISPUB.COM The Internet Journal of Genomics and Proteomics Volume 6 Number 2 Evaluation Of The Efficacy And Tolerability Of Micronutrient Supplementation In Treatment Of Post S Pandit, S Umbardand, V Ghodake,
More informationKnowledge and Perception of Menopause and Climacteric Symptoms among a Population of Women in Enugu, South East, Nigeria
Annals of Medical and Health Sciences Research January 211 Vol. 1 N.1 Knowledge and Perception of Menopause and Climacteric Symptoms among a Population of Women in Enugu, South East, Nigeria Ikeme ACC*,
More informationCASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
More informationEvaluation Of The Efficacy And Tolerability Of Micronutrient Supplementation In Treatment Of Post Menopausal Symptoms
1 of 6 4/24/2012 10:58 AM The Internet Journal of Gynecology and Obstetrics ISSN: 1528-8439 Evaluation Of The Efficacy And Tolerability Of Micronutrient Supplementation In Treatment Of Post Menopausal
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationMenopause Rating Scale (MRS) Development of the scale Identification of concept and domains to be measured
1 Menopause Rating Scale (MRS) Development of the scale 1 Status report by Lothar A.J. Heinemann March 2007 1. Conceptual framework and intended application 1.1. Identification of concept and domains to
More informationGabapentin to treat hot flashes
P ford residence southampton, ny Gabapentin to treat hot flashes 6-10-2010 An extendedrelease version of the seizure and pain drug gabapentin may be one step closer to becoming the first approved nonhormonal
More informationAssessment and Treatment of Depression in Menopause
Disclosures Assessment and Treatment of Depression in Menopause Susan G. Kornstein, MD Professor of Psychiatry and Obstetrics-Gynecology Executive Director, Institute for Women s Health Virginia Commonwealth
More informationproduced by post-menopausal women (MacDonald weight (Rizkallah et al. 1975; MacDonald et al. possible relationships among the climacteric symp
Climacteric symptoms, fat mass, and plasma concentrations of LH, FSH, Prl, oestradiol-17\gb\ and androstenedione in the early post-menopausal period C. Hagen, C. Christiansen, M. S. Christensen and I.
More informationDepartment of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament
Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics
More informationNeurontin for menopause symptoms
Neurontin for menopause symptoms The Borg System is 100 % Neurontin for menopause symptoms "I have a herniated disc in my back and it's protruding in my spine on my nerve. I was just prescribed Neurontin
More informationORIGINAL PAPERS. The Effects of Progesterone Selection on Psychological Symptoms in Hormone Replacement Therapy
ORIGINAL PAPERS Adv Clin Exp Med 2014, 23, 1, 63 67 ISSN 1899 5276 Copyright by Wroclaw Medical University Emel Kiyak Caglayan ¹, A, D, Mustafa Kara ¹, B, Sema Etiz 2, B, F, Pinar Kumru 3, C, D, Nurettin
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationCarolyn Pheteplace. Department of Obstetrics and Gynecology,
Department of Obstetrics and Gynecology, Harvard Medical School, and Department of Surgery, Peter Bent Brigham Hospital. Boston, Massachusetts, U. S. A. FOLLICLESTIMULATING HORMONE AND LUTEINIZING HORMONE
More informationOBSTETRICS & GYNECOLOGY
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationResearch Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women
Cronicon OPEN ACCESS PHARMACEUTICAL SCIENCE Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms Bungau S 1, Tit DM 1 *, Fodor K 1
More informationProduct: Femmerol. Client: Solutions for Women, LLC 315 North Village Avenue New York, (516)
CLINICAL TRIAL In 2002 the company completed an IRB (Institutional Review Board) Prospective, Randomized, Placebo-Controlled Clinical Trial. In Conclusion: Femmerol is effective in relieving a number of
More informationIf searching for the book Hot flashes.(clinical Guidelines For Family Physicians)(North American Menopause Society ): An article from: Family
Hot Flashes.(Clinical Guidelines For Family Physicians)(North American Menopause Society ): An Article From: Family Practice News [HTML] [Digital] By Priscilla Latta;Neil Skolnik READ ONLINE If searching
More informationIs Desvenlafaxine Effective for Reducing Hot Flashes In Postmenopausal Females?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Desvenlafaxine Effective for Reducing
More informationTraditional Chinese Medicine (TCM) in the Management of Menopausal Symptoms/Conditions
Introduction www.womenshealthclinic.co.uk Traditional Chinese Medicine (TCM) in the Management of Menopausal Symptoms/Conditions XY Zhang, PhD MD Women s Health Clinic, London, UK Email: xzhang@womenshealthclinic.co.uk
More informationPostpartum Depression
Clinical Medicine: Depression Postpartum Depression JMAJ 44(8): 354 358, 2001 Yoshiko MIYAOKA Department of Psychiatry, Tokyo Musashino Hospital Abstract: Both maternity blues and postpartum depression
More informationThe Better Health News2
October, 2016 Volume11, Issue 10 The Better Health News2 Special Interest Articles: Menopause and Bioflavonoids Osteoporosis and Exercise Bone Health: More than Calcium & Vitamin D Flax Seeds and Menopause
More informationJOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH How to cite this article: CHOWTA N K,SEBASTIAN J,CHOWTA M N.COMPARATIVE STUDY OF MENOPAUSAL SYMPTOMS IN POST MENOPAUSAL AND PERIMENOPAUSAL WOMEN.Journal of Clinical
More informationBy Katsuyuki Takahashi
Tohoku J. Exper. Med., 1961, 75, 207-222 On the Extra-Ovarian Origin of Estrogen By Katsuyuki Takahashi The Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai; Director
More informationEVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES
Int. J. Chem. Sci.: 6(3), 2008, 1228-1235 EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES RAMPRASAD DEY, SUBHASH CHANDRA BISWAS, RANU ROY BISWAS a and ARUNIMA MUKHOPADHYAY
More informationData Shows Reduction in Frequency and Severity in Hot Flashes in as Early as 14 Days
Newly Published Menopause Study: Bioidentical and FDA Approved Divigel (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated with Menopause Data Shows Reduction
More informationNAMS in the News 2016
NAMS in the News 2016 Menopause in the News This is great support showing that being sedentary is not only not good for your health, it is not good for your menopause symptoms, said Dr. JoAnn Pinkerton,
More informationIMPROVING THE QUALITY OF LIFE IN CLIMAX WITH KINETOTHERAPY AND NATURAL FACTORS IN VATRA DORNEI RESORT
IMPROVING THE QUALITY OF LIFE IN CLIMAX WITH KINETOTHERAPY AND NATURAL FACTORS IN VATRA DORNEI RESORT Maria Daniela Crăciun University "Stefan cel Mare" Suceava daniela_mariacr@yahoo.com Abstract Introduction
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationArizona Natural Medicine, L.L.C W. Ray Road, Suite 1, Chandler, AZ
MENOPAUSE: THE ROAD TO HARMONY by Dr. Sarv Varta Khalsa, N.M.D. Have you been feeling like your emotions are out of control lately? Do you feel irritable one minute, snapping impatiently at your family
More informationIs Extract ERr731 from the Rheum Rhaponticum Effective in Relieving Menopausal Symptoms in Women Aged 45 to 55 Years of Age?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Extract ERr731 from the Rheum Rhaponticum
More informationFirst and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S.
First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies The availability of Brisdelle (Paroxetine) capsules offers the millions
More informationOBSTETRICS & GYNECOLOGY
AUGUST 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: BHRT for Menopause
More informationHOW TO MAKE SENSE OF MENOPAUSE. by Steven. F. Hotze, M.D.
HOW TO MAKE SENSE OF MENOPAUSE by Steven. F. Hotze, M.D. INTRODUCTION Dr. Hotze is founder of Hotze Health & Wellness Center and author of the book Hormones, Health, and Happiness. He has enabled thousands
More informationThe Better Health News2
May, 201 Volume 8, Issue 5 The Better Health News2 Special Interest Articles: OSTEOPOROSIS AND VITAMIN K COQ10 AND BLOOD VESSEL LINING DYSMENORRHEA AND OMEGA-3 FATTY ACIDS TESTOSTERONE COQ10 AND ASTHMA
More informationThe Female Brain: Balancing Social Expectations with Your Own Health 10/30/12. Louann Brizendine, MD
BIOGRAPHY: The Female Brain: Balancing Social Expectations with Your Own Health 10/30/12 Louann Brizendine, MD DR LOUANN BRIZENDINE is a neuropsychiatrist who completed her degree in Neurobiology at UC
More informationLIE ASSAY OF GONADOTROPIN in human blood is one of the most important
Changes in Human Serum FSH Levels During the Normal Menstrual Cycle MASAO IGARASHI, M.D., JUNJI KAMIOKA, M.D., YOICHI EHARA, M.D., and SEIICHI MATSUMOTO, M.D. LIE ASSAY OF GONADOTROPIN in human blood is
More informationNEW SELECTIVE TISSUE ESTROGENIC ACTIVITY REGULATOR (STEAR) IN MENOPAUSAL THERAPY IN TAIWAN
ORIGINAL ARTICLE Tibolone Compliance and Efficacy in Women Living in Taiwan NEW SELECTIVE TISSUE ESTROGENIC ACTIVITY REGULATOR (STEAR) IN MENOPAUSAL THERAPY IN TAIWAN Kuan-Chong Chao*, Peng-Hui Wang, Ming-Shyen
More informationEfficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women
Short Communication Obstet Gynecol Sci 2017;60(2):213-217 https://doi.org/10.5468/ogs.2017.60.2.213 pissn 2287-8572 eissn 2287-8580 Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy
More informationNoven Receives FDA Approval of a New Indication with a New Dose for Minivelle (Estradiol Transdermal System)
Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle (Estradiol Transdermal System) Minivelle now approved for prevention of postmenopausal osteoporosis at all doses New 0.025
More informationDoes Black Cohosh Improve Anxiety/Depression Symptoms in Women Who Are Postmenopausal?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Black Cohosh Improve Anxiety/Depression
More informationThe effect of hormone therapy on women's quality of life in the first year of the Estonian Postmenopausal Hormone Therapy trial
https://helda.helsinki.fi The effect of hormone therapy on women's quality of life in the first year of the Estonian Postmenopausal Hormone Therapy trial Veerus, Piret 2012 Veerus, P, Hovi, S-L, Sevon,
More informationNortheast Ohio Urogynecology Patient History Intake Form. Last Name First Name Age. Date of Birth Race Referring Physician.
Northeast Ohio Urogynecology Patient History Intake Form Last Name _First Name Age_ Date of Birth Race Referring Physician Reason for Visit: _ Allergies: Preferred Lab (circle): QUEST LABCARE PLUS LABCORP
More informationEstetrol, the Next Generation of Hormone Therapy: Results of a Phase 2b Dose-finding Study in Postmenopausal Women (E4 Relief)
Estetrol, the Next Generation of Hormone Therapy: Results of a Phase 2b Dose-finding Study in Postmenopausal Women (E4 Relief) Prof Wulf H Utian Case Western Reserve University School of Medicine, Cleveland,
More informationTreatment of Mood Disorders in Midlife Women
Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN
More information1405 NE Douglas Lee s Summit, MO Phone: Date: Fax: Female Information and Health Summary
Tracy Dryer, RPh Sheryl Pfeiler, Pharm D, RPh 1405 NE Douglas Lee s Summit, MO 64086 Phone: 816-524-8444 Date: Fax: 816-246-5493 Female Information and Health Summary Name Date of Birth Address City/State/ZIP
More informationManagement of Menopausal Symptoms
Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of
More informationVaginal atrophy is a common condition
original article Oman Medical Journal [2017], Vol. 32, No. 1: 15 19 Treatment of Vaginal Atrophy with Vaginal Estrogen Cream in Menopausal Indian Women Maitri Shah 1 *, Zalak Karena 1, Sangita V. Patel
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 8, September 2014
YOGA! THE PHYSIOLOGICAL EFFECT ON CLIMACTERIC WOMEN DR.P.VANITHAMANI* *Asst. Professor (SS), Dept. of Physical Education, Avinashilingam University for Women, Coimbatore, Tamilnadu, India INTRODUCTION
More informationDrug Class Review on Estrogens
Drug Class Review on July 2004 Heidi D. Nelson, MD, MPH Peggy Nygren, MA Michele Freeman, MPH Benjamin K. S. Chan, MS Oregon Evidence-based Practice Center Oregon Health & Science University TABLE OF CONTENTS
More informationEvaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome
Received: 9 Jun. 2010 Accepted: 21 Sep. 2010 Original Article Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome Nahid Fathizadeh*, Elham
More informationSouthern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3
The WISDOM survey: Physicians Level of Comfort Prescribing Treatment for Vulvar and Vaginal Atrophy (VVA) Symptoms in Women with a Predisposition or History of Breast Cancer Lisa Larkin, MD 1 ; Michael
More informationTRIAL SYNOPSIS. Title: National, phase III, multicentre, double-blind, placebo controlled, randomised trial. Trial Design:
TRIAL SYNOPSIS Title: A Phase III randomised study of FOlic Acid supplementation in the management of Menopausal symptoms in cancer survivors and healthy postmenopausal women (FOAM Trial) Trial Design:
More informationHealthy Sleep Tips Along the Way!
Women and Sleep What You Will Learn The Benefits and Importance of Sleep States and Stages of the Sleep Cycle Unique Physiology of Women s Sleep Common Disorders in Women that Affect Sleep Women s Role
More informationRELATIONSHIP BETWEEN SOCIOMETRIC STATUS AND ANXIETY1. Nara Gakugei University
Japanese Psychological Research19 64, Vol.6, No.2, 67-71 RELATIONSHIP BETWEEN SOCIOMETRIC STATUS AND ANXIETY1 TOSHIMI UEDA2 Nara Gakugei University An attempt was made to explore intensively the relationship
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationMenopause Matters. Equity Office Staff Seminar 14 November 2018
Menopause Matters Equity Office Staff Seminar 14 November 2018 1 What to expect at menopause How to manage symptoms Support at work Dr Janice Brown Medical lead, The University of Auckland NZ representative,
More informationDrug Class Review on Estrogen for Treatment of Menopausal Symptoms and Prevention of Low Bone Density & Fractures. Final Report
Drug Class Review on Estrogen for Treatment of Menopausal Symptoms and Prevention of Low Bone Density & Fractures Final Report Heidi D. Nelson, MD, MPH Peggy Nygren, MA Benjamin K. S. Chan, MS Produced
More informationCentre for Menstrual Cycle and Ovulation Research at Eight: 2010 CeMCOR Anniversary Celebration
June 30, 2010 Centre for Menstrual Cycle and Ovulation Research at Eight: 2010 CeMCOR Anniversary Celebration by Dr. Jerilynn C. Prior, Scientific Director, Centre for Menstrual Cycle and Ovulation Research
More informationHormone Restoration and Support
Hormone Restoration and Support As a doctor with a strong interest in functional medicine, I strive to help my patients to achieve optimal health in the best ways I know how. This encompasses a combined,
More informationCharles E. Stoopack M.D. FACOG
Charles E. Stoopack M.D. FACOG 3240 Venado St! Carlsbad, CA 92009 Phone: 760-845-1692! Fax: 760-944-1333! E-Mail: cstoopack@ucsd.edu Education M.D. New York Medical College, Valhalla, N.Y., 1980 Michaelin
More informationHormonal Changes Following Low-Dosage Irradiation of Pituitary and Ovaries in Anovulatory Women
Hormonal Changes Following Low-Dosage Irradiation of Pituitary and Ovaries in Anovulatory Women Further Studies A. E. Rakoff, M.D. Tms PRESENTATION is a second progress report in a long-term study of the
More informationNew Treatments for Vaginal Health. Sarah Azad, MD El Camino Women s Medical Group
New Treatments for Vaginal Health There s Hope Sarah Azad, MD El Camino Women s Medical Group The Genitrourinary Syndrome of Menopause (GSM) Problems with genital health secondary to the changes that occur
More informationThe Scientific Evaluation of New Claims
The Scientific Evaluation of New Claims George C. Curtis University of Michigan Hospitals In the scientific world, the burden of proof for new claims is on the claimant. This is consistent with probabilities,
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More informationPheochromocytoma: Effects of Catecholamines
36 PHYSIOLOGY CASES AND PROBLEMS Case 8 Pheochromocytoma: Effects of Catecholamines Helen Ames is a 51-year-old homemaker who experienced what she thought were severe menopausal symptoms. These awful "attacks"
More informationSoy and hot flashes: Should the 2012 meta analysis be updated?
Soy and hot flashes: Should the 2012 meta analysis be updated? Mark Messina, PhD, MS Soy Nutrition Institute Nutrition Matters, Inc. Loma Linda University markjohnmessina@gmail.com August 23, 2018 The
More informationSex, hormones and the heart
Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationBy Lora A. Connor B.A., 2008, California State University, Long Beach
By Lora A. Connor B.A., 2008, California State University, Long Beach A Thesis Proposal December 2014 Committee Members: James Amirkhan, Ph.D. (Chair) Courtney Ahrens, Ph.D. Young-Hee Cho, Ph.D. Agenda
More informationMenopause & HRT. Rosie & Alex. Image:
Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationLife stress and hysterectomy-oophorectomy
Maturitas, 6 (1984) 319-325 Elsevier 319 MAT 00323 Life stress and hysterectomy-oophorectomy loor W. Kraaimaat and Arend T. Veeninga Academic Hospital, Utrecht, The Netherlands (Received 18 April 1984;
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationGenitourinary Symptoms of Menopause (GSM) Effects on Sexual Function
Genitourinary Symptoms of Menopause (GSM) Effects on Sexual Function Amanda Clark MD MCR NCMP Urogynecologist Co-authors: Joanna Bulkley PhD, Kate Beadle WHNP, NCMP, Michael Leo PhD, Ashley Stoneburner
More informationNoven Enters Co-Promotion Agreement with Shionogi for Brisdelle (Paroxetine) Capsules MIAMI and NEW YORK, January 13, 2014
Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle (Paroxetine) Capsules Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate
More informationMenopause Symptoms and Management: After Breast Cancer
Menopause Symptoms and Management: After Breast Cancer An Educational Webinar for Patients and their Caregivers Wen Shen, MD, MPH Division of Gynecologic Specialties July 27, 2018 1 Disclosure I have a
More informationEVALUATION OF THE REDUCTION OF THE TYPICAL SYMPTOMS OF MENOPAUSE AFTER TREATMENT WITH FITOFLAVON 80
EVALUATION OF THE REDUCTION OF THE TYPICAL SYMPTOMS OF MENOPAUSE AFTER TREATMENT WITH FITOFLAVON 80 Page 1 di 7 INTRODUCTION Even if is not a disease, the menopause may be accompanied by symptoms that
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More information06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:
Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion
More informationMenopause & HRT. Matt McKenna Elliot Davis
Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea
More informationPh.D. Research Scholar, II Associate Professor & Head, III Assistant Professor,
Problems and Symptoms of Women Working Through Menopause (A Study with Reference to IT & ITES Women Executives at Chennai, Bangalore, Hyderabad and Pondicherry) I shakila. P, II DR. P. Sridharan, III DR.
More informationAromatherapy Massage Affects Menopausal Symptoms in Korean Climacteric Women: A Pilot-Controlled Clinical Trial
Advance Access Publication 23 April 2007 ecam 2008;5(3)325 328 doi:10.1093/ecam/nem027 Original Article Aromatherapy Massage Affects Menopausal Symptoms in Korean Climacteric Women: A Pilot-Controlled
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More informationTilburg University. Hormonal Substitition during Menopause Maartens, L.W.; Leusink, G.; Pop, Victor. Published in: Maturitas
Tilburg University Hormonal Substitition during Menopause Maartens, L.W.; Leusink, G.; Pop, Victor Published in: Maturitas Document version: Publisher's PDF, also known as Version of record Publication
More informationAuthors' objectives To evaluate the efficacy of complementary and alternative therapies for the management of menopausal symptoms.
Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review Nedrow A, Miller J, Walker M, Nygren P, Huffman L H, Nelson H D CRD summary This review
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationDoes xanax help with hot flashes
Search Does xanax help with hot flashes Can Xanax be used to treat menopause? as clonidine and gabapentin can help with the hot flashes. and Dementia Patients Does Medicaid pay for. 9-4-2017 Xanax (Alprazolam)
More informationCHAPTER 5: SUMMARY AND CONCLUSION
CHAPTER 5: SUMMARY AND CONCLUSION Menopause, as part of a woman's aging process, does not warrant the definition of an estrogen deficiency disease against which a full-scale battle needs to be waged for
More information